Nurami Medical, a Haifa, Israel-based medical device R&D company which is developing technology that facilitates post-surgical healing of soft tissue, completed a fundraising round of up to $6m.
The round was led by Almeda Ventures, with participation from Leon Recanati’s private equity investment company, Glenrock.
The company intends to use the funds for completion of the ongoing clinical trial for its first product, ArtiFascia, intended for healing and repair of the dura following cranial neurosurgery, and to fund regulatory approval processes from the FDA and the CE. The clinical trial will test ArtiFascia in 90 patients, of which 13 have already been implanted with its graft.
ArtiFascia is a patented, synthetic dural graft that protects the brain after neurosurgeries by boosting dura regeneration, while preventing cerebral-spinal fluid (CSF) leakage, to protect both the brain itself and central nervous system. The technology is based on biodegradable, synthetic nanofibers with sealing properties for soft tissue healing. The company is actively developing additional products for healing and regeneration of soft tissues, which represents a $20 billion market.
Established in 2014 by Dr. Amir Bahar, Nora Nseir Manassa (Co-CEO and CTO) and NGT3VC venture capital fund, the company is also led by Hannoch Marksheid, Co-CEO. The active chairman of the board is Doron Birger.